

Xpert® Bladder Cancer Detection

Bibliography

Disclaimer: The following bibliography is prepared as a courtesy for our customers to identify recently published works relevant to the on-label use of the Xpert Bladder Cancer Monitor Test.

PUBLICATIONS

Kavcic N, et al. Clinical Evaluation of Two Non-Invasive Genetic Tests for Detection and Monitoring of Urothelial Carcinoma: Validation of UroVysion and Xpert Bladder Cancer Detection Test. Front Genet. 2022 Jun 6;13:839598. doi:10.3389/fgene.2022.839598

Van Valenberg FJP, et al. Validation of an mRNA-based Urine Test for the Detection of Bladder Cancer in Patients with Haematuria. Eur J Oncol. 2021 Feb;4(1):93–101. doi:10.1016/j.euo.2020.09.001

Wallace E, et al. Development of a 90-Minute Integrated Non-Invasive Urinary Assay for Bladder Cancer Detection. J Urol. 2018 Mar;199(3):655–662. doi:10.1016/j.juro.2017.09.141

POSTERS

D'Elia C, et al. Xpert Bladder Cancer Detection as a Diagnostic Tool in Upper Urinary Tract Urothelial Carcinoma: Preliminary Results. Poster presented at Annual Meeting of the European Association of Urology. 2020 Jul 17-21.

Pressler JB, et al. Assessment of the Role of a Novel mRNA-based Urine Assay (Xpert Bladder Cancer Detection) in the Assessment of Patients with Hematuria-Initial Results from a Cohort Study. Poster presented at Annual Meeting of the International Bladder Cancer Network. 2019 Oct 3–5. Aarhus, Denmark.

CE-IVD. In Vitro Diagnostic Medical Device. Not available in all countries.

Vira Solelh

CORPORATE HEADQUARTERS EUROPEAN HEADQUARTERS

904 Caribbean Drive Sunnyvale, CA 94089 USA TOLL FREE +1.888.336.2743

PHONE +1.408.541.4191 FAX +1.408.541.4192 FAX

81470 Maurens-Scopont France PHONE +33.563.82.53.00 +33.563.82.53.01 EMAIL cepheid@cepheideurope.fr www.Cepheidinternational.com

© 2022 Cepheid. 5101-01